Showing results (241-250 of 928) with videos related to

Sort By:
Pageof 93
The Lancet. Diabetes & Endocrinology|February 28, 2026
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort studyXuan-Mai T Nguyen, Yanping Li, Sébastien Czernichow, et al.
The Lancet. Diabetes & Endocrinology|May 11, 2026
Safety of biopsy in phaeochromocytoma and paraganglioma: an international, multicentre, retrospective cohort studyLiang Zhang, Gautier Tisserand, Yanting Shen, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2026
Secondary causes of diabetes: a crossroad of endocrinology and oncologyNicholas Ken-Yoong Hee, Quan-Hziung Lim, Kamlesh Khunti, et al.
The Lancet. Diabetes & Endocrinology|April 27, 2026
Burden and determinants of diabetes in sub-Saharan AfricaCharles Agyemang, John Tetteh, Maïmouna Ndour Mbaye, et al.
The Lancet. Diabetes & Endocrinology|April 27, 2026
Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised studyAgnès Linglart, Francesco Emma, Justine Bacchetta, et al.
The Lancet. Diabetes & Endocrinology|April 26, 2026
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trialEmma G Wilmot, Patrick Moore, Thozhukat Sathyapalan, et al.
The Lancet. Diabetes & Endocrinology|June 8, 2026
A quarter-century of progress: innovations in lipid medicine that transformed cardiovascular preventionLluís Masana, Josep Ribalta, Daiana Ibarretxe
The Lancet. Diabetes & Endocrinology|June 7, 2026
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a studyVanita R Aroda, Raffaella Buzzetti, Stine-Mathilde Dalskov, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2026
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 studyJohn B Buse, Harpreet S Bajaj, Stine-Mathilde Dalskov, et al.
The Lancet. Diabetes & Endocrinology|March 11, 2019
Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trialMichael E J Lean, Wilma S Leslie, Alison C Barnes, et al.
Pageof 93